Misuse of Drugs Act 1971 (Temporary Class Drug) (No. 2) Order 2016 — House of Lords, 2016-12-15
Topic: Mixed Topics
Susan Williams (Conservative, Centre-right): My Lords, I extend my thanks to the Advisory Council on the Misuse of Drugs for its advice, which has informed the order. I also congratulate Dr Owen Bowden-Jones on his appointment as the new chair of the council, as announced in yesterday’s Written Ministerial Statement This order relates to methiopropamine, commonly known as MPA, as well as to its simple derivatives. This compound has been controlled under a previous temporary class drug order—a TCDO—which expired on 26 November 2016. If this order is made, MPA, as well as its simple derivatives, will be subject to temporary control under Section 2A of the Misuse of Drugs Act 1971 for a further 12 months. This will allow the ACMD to gather and consider more evidence in order to make a substantiated recommendation for permanent control under the Misuse of Drugs Act 1971 MPA is a stimulant psychoactive substance which is similar in its chemistry to methamphetamine and has similar effects to that substance, such as stimulation, alertness and an increase of energy and focus. Side-effects reported include abnormally fast heart rates, anxiety, panic attacks, perspiration, headaches, nausea, difficulty breathing, vomiting, difficulty urinating and sexual dysfunction The ACMD has reported that MPA initially emerged as a replacement drug for the methylphenidate-based compounds which had been temporarily controlled under a previous TCDO. Of particular concern was the potential high risk of bacterial infection and local tissue damage due to MPA being injected The ACMD notes that the initial TCDO has been effective in halting the problematic proliferation of MPA since it was first introduced in November 2015. The effectiveness of the TCDO has been particularly evident in areas of Scotland where instances had been reported previously. Although anecdotal, the evidence indicates that the prevalence and the use seen prior to the TCDO seem to have abated, particularly in relation to intravenous injection. Notably, Police Scotland, which initially alerted the ACMD to the possible displacement of MPA from ethylphenidate has reported reduced instances of injecting MPA; the number of phone call and database inquiries to TOXBASE—part of the National Poisons Information Service, which provides NHS healthcare professionals with a 24-hour, year-round clinical toxicology information service—regarding MPA have reportedly decreased; and there has been a reported decrease in the availability of MPA in online markets Parliament’s approval of this order will enable UK law enforcement to continue action against traffickers and suppliers of temporary class drugs while the ACMD gathers evidence. The order also sends out a clear message to the public, especially to young people, that these drugs carry serious health risks. We know that the law cannot, on its own, deter all those inclined to use or experiment with these drugs. However, we expect the TCDO to continue to have a notable impact on the availability of and in turn the demand for these drugs As well as our legislative response, we continue to take action to reduce the demand for drugs and ensure that those who become dependent have access to the support that they need to recover. We will continue to update our public health messages to inform the public of the harms of new psychoactive substances using the latest evidence gathered from early warning systems. With that, and apologies for the use of so many acronyms, I beg to move.